Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?

Troiani T, Martinelli E, Morgillo F, Capasso A, Nappi A, Sforza V, Ciardiello F.

Ther Adv Med Oncol. 2013 Jan;5(1):51-72. doi: 10.1177/1758834012462462.

2.

Targeting signal transduction pathways in colorectal cancer--more than skin deep.

Cohen SJ, Cohen RB, Meropol NJ.

J Clin Oncol. 2005 Aug 10;23(23):5374-85. Epub 2005 Jul 5. Review.

PMID:
15998904
3.
4.

Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.

Ramos FJ, Macarulla T, Capdevila J, Elez E, Tabernero J.

Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S52-7. doi: 10.3816/CCC.2008.s.008. Review.

PMID:
19064407
5.

Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.

Venook AP.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S74-84. Review.

PMID:
19780248
6.

Monoclonal antibodies in the treatment of advanced colorectal cancer.

Capdevila J, Saura C, Macarulla T, Casado E, Ramos FJ, Tabernero J.

Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S24-34. Epub 2007 Nov 5. Review.

PMID:
17981431
7.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
8.

Emerging targeted therapies for breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

J Clin Oncol. 2010 Jul 10;28(20):3366-79. doi: 10.1200/JCO.2009.25.4011. Epub 2010 Jun 7. Review.

PMID:
20530283
9.

Therapeutics targeting signal transduction for patients with colorectal carcinoma.

de Bono JS, Rowinsky EK.

Br Med Bull. 2002;64:227-54. Review.

PMID:
12421735
10.

[Molecular targets in colon cancer].

Borner MM.

Ther Umsch. 2006 Apr;63(4):243-8. Review. German.

PMID:
16689454
11.

Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.

Winder T, Lenz HJ.

Gastroenterology. 2010 Jun;138(6):2163-76. doi: 10.1053/j.gastro.2010.02.005. Review.

PMID:
20420953
12.

Molecularly targeted therapy for gastrointestinal cancer.

Wiedmann MW, Caca K.

Curr Cancer Drug Targets. 2005 May;5(3):171-93. Review.

PMID:
15892618
13.

Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).

Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M.

Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Review.

14.
15.

A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer.

Gilmour AM, Abdulkhalek S, Cheng TS, Alghamdi F, Jayanth P, O'Shea LK, Geen O, Arvizu LA, Szewczuk MR.

Cell Signal. 2013 Dec;25(12):2587-603. doi: 10.1016/j.cellsig.2013.08.008. Epub 2013 Aug 30.

16.

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

Amador ML, Hidalgo M.

Clin Colorectal Cancer. 2004 May;4(1):51-62. Review.

PMID:
15207021
17.

Prognostic significance and targeting of HER family in colorectal cancer.

Khelwatty SA, Essapen S, Seddon AM, Modjtahedi H.

Front Biosci (Landmark Ed). 2013 Jan 1;18:394-421. Review.

PMID:
23276932
18.

Targeted therapy of metastatic breast cancer.

Sánchez-Muñoz A, Pérez-Ruiz E, Jiménez B, Ribelles N, Márquez A, García-Ríos I, Alba Conejo E.

Clin Transl Oncol. 2009 Oct;11(10):643-50. Review.

PMID:
19828406
19.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
20.

Targeted Therapy for NSCLC--A Double-edged Sword?

Dempke WC.

Anticancer Res. 2015 May;35(5):2503-12. Review.

PMID:
25964523

Supplemental Content

Support Center